Evidence map›Paper›PMID 32802331›Full record

ArticleMolecular and clinical oncology2020

Feasibility and efficacy of chemoradiotherapy with concurrent split-dose cisplatin after induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for locally advanced head and neck cancer.

Tomoya Yokota, Masayuki Shibata, Satoshi Hamauchi, Hiromichi Shirasu, Yusuke Onozawa, Hirofumi Ogawa, Tsuyoshi Onoe, Takeshi Kawakami, Mitsuhiro Furuta, Hiroto Inoue and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Tomoya YokotaDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Masayuki ShibataDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Satoshi HamauchiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Hiromichi ShirasuDivision of Medical Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Yusuke OnozawaDivision of Medical Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Hirofumi OgawaDivision of Radiation Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Tsuyoshi OnoeDivision of Radiation Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Takeshi KawakamiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Mitsuhiro FurutaDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Hiroto InoueDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Kunihiro FushikiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Tetsuro OnitsukaDivision of Head and Neck Surgery, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.
Shizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoradiotherapy (CRT) with concurrent high-dose cisplatin (CDDP) is a standard treatment for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Docetaxel plus CDDP and 5-fluorouracil (TPF) induction chemotherapy (ICT) prior to CRT is considered for patients at high risk of distant metastases. The purpose of the current study was to evaluate the feasibility and efficacy of CRT with split-dose CDDP after TPF-ICT for LA-SCCHN. A total of 21 LA-SCCHN patients treated with TPF-ICT followed by concurrent CRT with split-dose CDDP between January 2011 and December 2017 were retrospectively analysed. The patients' characteristics were i) median age 66 years (48-75 years); ii) male/female, 21/0; iii) performance status 0-1/2, 20/1; iv) larynx/hypopharynx/oropharynx/oral cavity, 4/8/8/1 and v) clinical stage III/IV, 3/18. The numbers of TPF-ICT cycles 1/2/3 were 2/3/16. Median cumulative doses of CDDP in TPF-ICT and CRT were 180.0 and 206.7 mg/m

Indexed as

chemoradiotherapyinduction chemotherapylocally advanced squamous cell carcinoma of the head and necknephrotoxicityneurotoxicityototoxicitysplit-dose concurrent high-dose cisplatin

Identifiers

PMID32802331
PMCPMC7412679
OpenAlexW3046660125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.